What question did this study set out to answer?

The study aims to characterize very early axial spondyloarthritis and evaluate TNF inhibitor effectiveness compared to established disease.

March 7, 2026RMD OpenOpen Access

Effectiveness of TNF inhibitors in patients with very early axial spondyloarthritis, defined as duration of ≤1 year of back pain: longitudinal observational data from the SCQM registry

View Full Paper

Ask AI

Bookmark

The study aims to characterize very early axial spondyloarthritis and evaluate TNF inhibitor effectiveness compared to established disease.
Included 3324 patients with axial spondyloarthritis from a registry.
Categorized patients based on duration of back pain (≤1 year, >1 and ≤2 years, >2 years).
Compared disease activity achievement using ASDAS at 1 year and analyzed drug survival with adjusted models.
Objective signs of inflammation were more common in very early disease.
No significant difference in achieving low disease activity (ASDAS <2.1) in very early vs established axSpA (OR 1.08).
TNFi retention was similar in very early versus established axSpA (HR 1.05).

No takes yet. Share an insight, caveat, or question.

Observational data reveals no difference in TNF inhibitor effectiveness between early and established axSpA.

Bachmann et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark